Unique ID issued by UMIN | UMIN000028741 |
---|---|
Receipt number | R000032874 |
Scientific Title | A multicenter retrospective study on efficacy and safety of salvage surgery for primary lung cancer |
Date of disclosure of the study information | 2017/08/21 |
Last modified on | 2019/07/04 05:51:15 |
A multicenter retrospective study on efficacy and safety of salvage surgery for primary lung cancer
A multicenter retrospective study on efficacy and safety of salvage surgery for primary lung cancer
A multicenter retrospective study on efficacy and safety of salvage surgery for primary lung cancer
A multicenter retrospective study on efficacy and safety of salvage surgery for primary lung cancer
Japan |
primary lung cancer
Chest surgery |
Malignancy
YES
To clarify the efficacy and safety of salvage surgery for remnant or recurernce of primary lung cancer after definitive radiation/ definitive chemoradiotherapy/ stereotactic radiotherapy, ion radiotherapy/ molecular targeted therapy.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
3-year overall survival rate
Adverse event, Incidence of complications, Perioperative mortality, 3-year recurrence free survival rate, Median survival time
Observational
Not applicable |
Not applicable |
Male and Female
A) Patient who underwent salvage surgery after
definitive CRT/RT, stereotactic radiation, ion beam therapy.
1) Patient who underwent salvage surgery between 1/1/2010 and 12/31/2015.
2) Primary lung cancer was proven pathologically at any point in time.
3) Patient who could not complete the initial therapy because of adverse event or complication is also eligible, if the initial therapy was intended radical treatment.
4) Three years passed after salvage surgery.
B) Patient who underwent salvage surgery after molecular targeted therapy(EGFR-TKI or ALK inhibitor).
1) Patient who underwent salvage surgery between 1/1/2010 and 12/31/2015.
2) Primary lung cancer was proven pathologically at any point in time.
3) EGFR-TKI or ALK inhibitor was administrated.
4) Three years passed after salvage surgery.
5) EGFR mutation status and ALK rearrangement status do not matter.
1) Patient treated as induction therapy intentionally.
2) Patient who underwent resection not for local lesion (other than lung or regional lymph node).
3) Patient who was treated with molecular targeted therapy other than EGFR-TKI or ALK inhibitor as molecular targeted therapy.
4) Patient who withdrew the consent of this study.
5) Patient who was considered inappropriate to this study by attending doctor.
400
1st name | |
Middle name | |
Last name | Kimihiro Shimizu |
Gunma University Hospital
Division of General Thoracic Surgery, Integrative Center of General Surgery
3-39-15 Showa-machi, Maebashi, Gunma
027-220-8245
kmshimizu@gmail.com
1st name | |
Middle name | |
Last name | Yoichi Ohtaki, Kimihiro Shimizu |
Gunma University Hospital
Division of General Thoracic Surgery, Integrative Center of General Surgery
3-39-15 Showa-machi, Maebashi, Gunma
027-220-8245
yohtakiadvanced@gmail.com
Division of General Thoracic Surgery, Integrative Center of General Surgery, Gunma University Hospital
The Japanese Association for Chest Surgery
Non profit foundation
Japan
NO
群馬大学医学部付属病院(群馬)
2017 | Year | 08 | Month | 21 | Day |
Unpublished
Completed
2016 | Year | 09 | Month | 15 | Day |
2017 | Year | 01 | Month | 26 | Day |
2016 | Year | 10 | Month | 01 | Day |
2019 | Year | 08 | Month | 31 | Day |
Design: multicenter retrospective observational study using central registration system
Registration method: Electronic Data Capture system
2017 | Year | 08 | Month | 19 | Day |
2019 | Year | 07 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032874